VRDN · Viridian Therapeutics, Inc.
$19.27
-0.96% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-7.5
Dividend yield
—
Beta
0.90
Avg volume
3M
Employees
0K
2D change
—
5D change
2.28%
10D change
9.26%
30D change
10.06%
60D change
11.80%
MTD change
6.60%
YTD change
-36.70%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — VRDN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-30
Latest call per bank · past 12 months
RBC Capital
Outperform$35.00
+81.6% vs priceWells Fargo
Overweight$31.00
+60.9% vs priceGoldman Sachs
Buy$31.00
+60.9% vs priceUBS
Buy$50.00
+159.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-30 | RBC Capital | Maintains | Outperform | $34.00 → $35.00 |
| 2026-06-30 | Truist Securities | Maintains | Buy | $35.00 → $38.00 |
| 2026-06-30 | Wedbush | Maintains | Outperform | $32.00 → $43.00 |
| 2026-06-30 | Needham | Maintains | Buy | $32.00 → $34.00 |
| 2026-06-29 | Wells Fargo | Upgrade | Equal-Weight → Overweight | $20.00 → $31.00 |
| 2026-06-29 | Needham | Reiterates | Buy | $32.00 |
| 2026-05-15 | Evercore ISI Group | Maintains | Outperform | $27.00 → $26.00 |
| 2026-05-06 | RBC Capital | Maintains | Outperform | $30.00 → $34.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 58 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 10.1% above the 50-day MA ($17.72).
- Price vs 200-day MA: Trading 18.8% below the 200-day MA ($24.03).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.03) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($13.30) and high ($33.78).
VRDN Price Chart
Loading chart for VRDN…
Fundamentals
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.